[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353756-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353756-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinically-actionable-stratification-of-uncommon-met-fusions-a-precision-oncology-framework","Clinically actionable stratification of uncommon MET fusions - a precision oncology framework","","MET fusions are emerging therapeutic targets in solid tumors, yet functional interpretation of non-canonical variants remains poorly defined, limiting precision oncology decisions. A multicenter pan-cancer analysis of 23,299 clinical specimens used DNA-based next-generation sequencing to profile MET fusions, with RNA-based NGS transcriptional validation on available samples. Preliminary clinical outcomes were evaluated in four advanced cancer patients receiving MET tyrosine kinase inhibitors, showing early evidence of activity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinically-actionable-stratification-of-uncommon-met-fusions-a-precision-oncology-framework/353756/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinically-actionable-stratification-of-uncommon-met-fusions-a-precision-oncology-framework/353756.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main research focus regarding uncommon MET fusions?","Question",{"text":63,"@type":64},"The study evaluates how uncommon, non-canonical MET fusions can be stratified for clinical actionability and how their genomic findings relate to functional transcriptional outputs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were MET fusions profiled and validated in this work?",{"text":68,"@type":64},"DNA-based next-generation sequencing profiled MET fusions across 23,299 clinical samples, and RNA-based NGS transcriptional validation was performed on available specimens.",{"name":70,"@type":61,"acceptedAnswer":71},"What clinical activity was observed after MET TKI therapy in patients with uncommon MET fusions?",{"text":72,"@type":64},"In four advanced cancer patients treated with MET tyrosine kinase inhibitors, all achieved partial responses, including cases of pediatric diffuse midline glioma and lung adenocarcinoma.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353756,1790198274,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Yang et al. Journal of Translational Medicine (2026) 24:293  \n[https://doi.org/10.1186/s12967-026-07689-y](https://doi.org/10.1186/s12967-026-07689-y)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nClinically actionable stratification of uncommon METfusions: a precision oncology framework  \nWenhui Yang1†, Yanxiang Zhang2†, Tonghui Ma3†, Haiyang Liang4†, Qingsheng Xu5, Mingyao Lai6, Lusheng Li7 and Haozhe Piao4*  \nAbstract  \nBackground MET fusions represent emerging therapeutic targets in solid tumors; however, functional interpretation of non-canonical variants remains poorly understood, posing a major challenge for precision oncology.  \nMethods We conducted a multicenter, pan-cancer study analyzing 23,299 clinical samples using DNA-based nextgeneration sequencing (NGS) to profile MET fusions. Transcriptional validation was performed using RNA-based NGS on available samples. Preliminary clinical outcomes were assessed in four patients with advanced malignancies harboring uncommon METfusions who received MET tyrosine kinase inhibitor therapy.  \nResults We identified 116 MET fusions (incidence: 0 . 5%), with 55. 2%(64/116) classified as uncommon fusions. These uncommon fusions were stratified into: Group A (5’-retained, n = 12), Group B (intergenic/exonic breakpoints, n = 19), Group C (rare partners, n = 23), and Group D (dual fusions, n = 10) . RNA validation revealed an overall low transcriptional consistency of 43 . 8%(14/32) for uncommon fusions, versus 100% for canonical fusions (PTPRZ1::MET, CAPZA2::MET) . Notably, most 5’-retained fusions were transcriptionally silent, while some intergenic fusions resolved into expressed canonical partners (e. g. PTPRZ1::MET) . Therapeutically, all four MET inhibitor-treated patients achieved partial responses, including pediatric diffuse midline gliomas (DMG) (median OS: 11.2 months) and lung  \nadenocarcinoma (median OS: 34 months), demonstrating preliminary clinical activity.  \nConclusions uncommon MET fusions are heterogeneous at genomic and transcriptional levels. DNA-level findings often do not predict functional transcripts, underscoring the necessity of RNA-based confirmation for clinical interpretation. Despite low overall consistency, a subset retains therapeutic potential. We propose a refined diagnostic framework integrating DNA-based stratification and RNA validation to guide the management of MET-altered cancersin precision oncology workflows.  \nKeywords Biomarker-driven therapies, MET, MET inhibitor, NGS, MET  \n†Wenhui Yang, Yanxiang Zhang, Tonghui Ma and Haiyang Liang contributed equally to this study.  \n*Correspondence:  \nHaozhe Piao[piaohz1964@outlook.com](piaohz1964@outlook.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nYang et al. Journal of Translational Medicine (2026) 24:293  \nIntroduction  \nThe ","cbCaibANHgOvdxJx","https://ap.wps.com/l/cbCaibANHgOvdxJx","pdf",2262869,12,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main research focus regarding uncommon MET fusions?\",\"answer\":\"The study evaluates how uncommon, non-canonical MET fusions can be stratified for clinical actionability and how their genomic findings relate to functional transcriptional outputs.\"},{\"question\":\"How were MET fusions profiled and validated in this work?\",\"answer\":\"DNA-based next-generation sequencing profiled MET fusions across 23,299 clinical samples, and RNA-based NGS transcriptional validation was performed on available specimens.\"},{\"question\":\"What clinical activity was observed after MET TKI therapy in patients with uncommon MET fusions?\",\"answer\":\"In four advanced cancer patients treated with MET tyrosine kinase inhibitors, all achieved partial responses, including cases of pediatric diffuse midline glioma and lung adenocarcinoma.\"}]","Clinically actionable stratification of uncommon MET fusions - a precision oncology framework | PDF",1790107075,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a820c19f630e6a80e7c4a90a1cf36ad.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f39a0b7c543714cbb1210bc936613581.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afa46e07fcfcce229aa1bcb70e51d967.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b3782045b86ec8fe16d7eef880d2dbe.webp",980,1306]